Members of Perrigo's Board of Directors
Moshe Arkin, 56, has been a director of Perrigo since March 2005 and served as Vice
Chairman from March 2005 until his retirement on March 17, 2008. He served as
Chairman of the Board of Directors and was the principal shareholder of Agis Industries
(1983) Ltd., now known as Perrigo Israel Pharmaceuticals Ltd., from its establishment in
1983 (and prior to that of its affiliated companies) until its acquisition by Perrigo in March
2005. He also served as President of that company from December 2000 until March
2008. Mr. Arkin is Chairman of the Board for Exalenz Bioscience Ltd., a developer of
specialized medical diagnostic equipment, and Chairman of Mobile Solids a developer of
software solutions for mobile devices. Mr. Arkin resides in Israel.
Laurie Brlas, 51, has been a director of Perrigo since August 2003 and has served as
Chair of the Audit Committee since October 2004. Since March 2008, Ms. Brlas has
served as Executive Vice President, Chief Financial Officer of Cliffs Natural Resources,
Inc. (formerly Cleveland Cliffs, Inc.), the largest producer of iron ore pellets in North
America. Previously at Cliff's Natural Resources, Inc., Ms. Brlas served as Senior Vice
President from December 2006 to March 2008 and Treasurer from December 2006 to
November 2007. Prior to that Ms. Brlas served as Senior Vice President and Chief
Financial Officer of STERIS Corporation from April 2000 through November 2006.
From September 1995 through March 2000, Ms. Brlas held various positions with
Office Max, Inc., most recently as Senior Vice President and Corporate Controller.
Gary M. Cohen, 50, has been a director of Perrigo since January 2003 and served as
Lead Independent Director from August 2008 to August 2009. Since June 2006, he
has served as Executive Vice President of Becton, Dickinson and Company (BD), a
provider of medical supplies, devices, laboratory equipment and diagnostic systems.
He also served as President of BD Medical, one of three business segments of BD from
May 1999 until June 2006. Mr. Cohen has been an executive officer of BD in various
capacities since October 1996. Mr. Cohen presently serves as a director and secretary
of the United States Fund for UNICEF, director of the Centers for Disease Control
(CDC) Foundation as well as chairperson of the CDC Corporate Roundtable, and
director of Accordia Health Foundation.
David T. Gibbons, 66, has been a director of Perrigo since June 2000. Between
March 2008 and February 2009, he served as Interim Chief Executive Officer of
Cott Corporation, a leading provider of non-alcoholic beverages and store brand
soft drinks. He has served on Cott's board of directors since 2007 and is currently
Chairman of the Board. Mr. Gibbons served as Executive Chairman of Perrigo from
October 9, 2006 until his retirement in March 2007. Prior to that, Mr. Gibbons
served as the President and Chief Executive Officer of Perrigo from May 2000 to
October 2006 and as Chairman of the Board from August 2003 to October 2007.
He served as President of Rubbermaid Europe from August 1997 to April 1999 and
as President of Rubbermaid Home Products from December 1995 to August 1997.
Prior to joining Rubbermaid, Mr. Gibbons served in a variety of general management,
sales and marketing positions during his 27-year career with 3M Company. Mr.
Gibbons is also a director of Robbins & Myers, Inc., a supplier of application-critical
equipment and systems to the global pharmaceutical, energy and industrial markets.
Ran Gottfried, 65, has been a director of Perrigo since February 2006. From July
2006 to December 2008, Mr. Gottfried served as Chairman and CEO of Powerpaper
Ltd., a leading developer and manufacturer of micro-electrical cosmetic and
pharmaceutical patches. Since 1975 he has served as a CEO, consultant and director
of private and public companies in Israel and Europe in the areas of retail and distribution,
pharmaceuticals, and telecommunications. From January 2001 until December 2005, he
served as Chairman of Magnolia Silver Jewelry, Ltd. Mr. Gottfried also served as an
advisor to Careline-Neca, a consumer division of the Company’s Perrigo Israel subsidiary
from 2004 until March 2007 when his consulting ended. Mr. Gottfried was also a director
of Agis Industries (1983) Ltd., one of Israel’s largest pharmaceutical companies from 2003
until its acquisition by Perrigo in March 2005. Mr. Gottfried is also a director of Bezeq,
Israel’s leading telecommunications provider. Mr. Gottfried resides in Israel.
Ellen R. Hoffing, 52, has been a director of Perrigo since July 2008. Since September
2009, Ms. Hoffing has served as Chief Operating Officer and Co-President of Neos
Therapeutics, a privately held specialty pharmaceutical company that focuses on
extended release liquid drug development. From September 2006 until September
2009 she served as President and Chief Executive Officer of Applied NeuroSolutions,
Inc., a development stage biopharmaceutical company focused on diagnostics and
therapeutics for the treatment of Alzheimer’s disease. She has also served as Chairman
of Applied NeuroSolutions’ Board of Directors since December 2007 and will remain
in that role. Ms. Hoffing’s extensive experience in the pharmaceutical industry includes
senior positions at American Pharmaceutical Partners, from March 2005 to November
2005, Baxter Healthcare, from November 2002 to March 2005 and G.D. Searle
from September 1983 to October 2000.
Michael J. Jandernoa, 59, has been a director of Perrigo since January 1981 and
has served as Chair of the Compensation Committee since October 2007. He served
as Perrigo’s Chief Executive Officer from February 1988 through April 2000 and as
Chairman of the Board from October 1991 to August 2003. Mr. Jandernoa also
served in various other executive capacities with Perrigo since 1979. He is a general
partner of Bridge Street Capital Fund 1, LP; a director of Fifth Third Bank – West
Michigan, a Michigan banking corporation; and a director of Steelcase, Inc., a
manufacturer of case good products and furniture systems for the office furniture
industry. Mr. Jandernoa also serves on the Board of the Strategic Economic
Investment and Commercial Board (SEIC) (formerly Michigan Technology Tri-Corridor
and Life Science Corridor).
Gary K. Kunkle, Jr., 62, has been a director of Perrigo since October 2002 and
has served as Lead Independent Director from August 2007 to August 2008 and since
August 2009. He also served as the Chair of the Compensation Committee from May
2006 until October 2007. Mr. Kunkle served as Chairman and Chief Executive Officer
of DENTSPLY International Inc., a manufacturer and marketer of products for the
professional dental market from January 2004 until his retirement in December 2006.
He previously served as President and Chief Operating Officer of DENTSPLY from
January 1997 to December 2003. He also was a director of that company from March
2002 until December 31, 2006. From January 1994 to December 1996, he served as
President of Vistakon, a division of Johnson & Johnson.
Herman Morris, Jr., 58, has been a director of Perrigo since December 1999 and
served as Chair of the Nominating & Governance Committee since October 2007.
Since September 2006, he has been in the private practice of law in Memphis,
Tennessee. From April 2006 until September 2006, Mr. Morris was Vice President
and General Counsel of Pinnacle Airlines. Mr. Morris was a partner in the Baker,
Donaldson, Bearman, Caldwell and Berkowitz Law Firm in Memphis, Tennessee
from April 2004 to June 2006. He served as President and Chief Executive Officer
of Memphis Light, Gas and Water Division from August 1997 until January 2004.
Prior to that Mr. Morris was General Counsel of Memphis Light, Gas and Water
Division.
Joseph C. Papa, 54, joined Perrigo in October 2006 as President and Chief
Executive Officer and was elected to the Board of Directors in November 2006
and appointed Chairman of the Board in October 2007. He previously served as
Chairman and Chief Executive Officer of the Pharmaceutical and Technologies
Services segment of Cardinal Health. from December 2004 to October 2006.
Prior to that position he served as President and Chief Operating Officer of Watson
Pharmaceuticals from 2001 to 2004. Additionally, he has held management
positions at DuPont Pharmaceuticals, Pharmacia Corporation, G.D. Searle &
Company and Novartis AG. Mr. Papa is a director of Smith & Nephew, a
developer of advanced orthopedic medical devices.
Ben-Zion Zilberfarb, 59, has been a director of Perrigo since February 2007.
Since 1978 he has served as a consultant and director for private and public
companies in the areas of banking, insurance, and private capital. He has also
served as a Professor of Economics at Bar-Ilan University and the Edmond de
Rothschild Professor of Global Asset Management at Netanya Academic College
since 1988 and 2004, respectively. From 1998 to 1999 he was Director General
of Israel's Ministry of Finance. He is a Board member and Chairman of the Audit
Committee for Delek Group, a holding an management company investing in Israel
and abroad, and for the Israel Discount Bank, both of which are traded on the Tel
Aviv Stock Exchange. He was a member of the Board and Audit Committee for
FundTech, Ltd. from 2002 to 2007, and of Partner Communication from 2000
until 2006. Mr. Zilberfarb resides in Israel.